Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Amgen (NASDAQ: AMGN) wins EC approval for UPLIZNA in generalized myasthenia gravis market European Commission clears Amgen Inc.’s UPLIZNA for generalized myasthenia gravis. Discover what this means for competition, pricing, and the autoimmune drug market. byPallavi MadhirajuFebruary 12, 2026